Vaxcyte, Inc. Director Retires; John Markels Appointed to Board

What Happened Vaxcyte, Inc. filed an 8-K disclosing that long‑time director Heath Lukatch notified the Board of his retirement, effective July 16, 2026, and that John Markels was appointed to the Board the same day. Dr. Lukatch’s retirement was not the result of any disagreement with the company. Dr. Markels will serve as a Class II director until the 2028 annual meeting and has been named to the Board’s Audit Committee and Compensation Committee.

Key Details

• Heath Lukatch’s retirement effective: July 16, 2026; served on the Board for more than eight years.
• John Markels appointment effective: July 16, 2026; term expires at the 2028 annual meeting.
• Board determinations: Dr. Markels is independent under Nasdaq Rule 5605(a)(2).
• Compensation and arrangements: Dr. Markels will receive standard non‑employee director pay per Vaxcyte’s Director Compensation Program (annual equity grant equivalent currently set at $430,000) and has entered into the company’s standard indemnification agreement. The company reported no related‑party transactions or arrangements requiring disclosure under Item 404.

Why It Matters Board changes affect corporate governance and oversight. Adding an independent director who will serve on both the Audit and Compensation Committees could influence financial oversight and executive pay governance. The filing notes this is a routine, non‑dispute retirement and that compensation and indemnification follow standard company practices, indicating no unexpected governance or related‑party issues for investors.